Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index.

Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions

Open access

Abstract

Alzheimer’s disease (AD) clinical trials, focused on disease modifying drugs and conducted in patients with mild to moderate AD, as well as prodromal (early) AD, have failed to reach efficacy endpoints in improving cognitive function in most cases to date or have been terminated due to adverse events. Drugs that have reached clinical stage were reviewed using web resources (such as clinicaltrials.gov, alzforum.org, company press releases, and peer reviewed literature) to identify late stage (Phase II and Phase III) efficacy clinical trials and summarize reasons for their failure. For each drug, only the latest clinical trials and ongoing trials that aimed at improving cognitive function were included in the analysis. Here we highlight the potential reasons that have hindered clinical success, including clinical trial design and choice of outcome measures, heterogeneity of patient populations, difficulties in diagnosing and staging the disease, drug design, mechanism of action, and toxicity related to the long-term use. We review and suggest approaches for AD clinical trial design aimed at improving our ability to identify novel therapies for this devastating disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-190507

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig.1 Schematic Representation of Therapeutic Strategies. 1) Enhancement of neurotransmission; 2) Reduction of Aβ production and aggregation; 3) Enhancement of Aβ clearance; 4) Prevention of tau aggregation; 5) Anti-inflammatory agents; 6) Enhancement of microglial phagocytosis.
Fig.1 Schematic Representation of Therapeutic Strategies. 1) Enhancement of neurotransmission; 2) Reduction of Aβ production and aggregation; 3) Enhancement of Aβ clearance; 4) Prevention of tau aggregation; 5) Anti-inflammatory agents; 6) Enhancement of microglial phagocytosis.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 102 references

Research works printed but not linked: 13

  1. Tanzi RE, 2013, J Alzheimers Dis, 33, S5
  2. 10.1046/j.1460-9568.2000.01344.x · doi:10.1046/j.1460-9568.2000.01344.x
  3. Wilcock DM, 2012, Int J Alzheimers Dis, 2012, 495243
  4. Lilly Press Release, Update on https://investor.lilly.com/node/39051/pdf 3 Clinical Trials of Lanabecestat for Alzheimer’s Disease. https://investor.lilly.com/node/39051/pdf, Posted June 12, 2018, Accessed February13, 2019.
  5. Coric V, 2012, Arch Neurol, 3, 1
  6. Biogen Press Release, Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of Aducanumab in Alzheimer’s Disease, http://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials, Posted March 21, 2019, Accessed March 29, 2019.
  7. Biogen Press Release, Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months, http://investors.biogen.com/news-releases/news-release-details/eisai-and-biogen-announce-positive-topline-results-final, Posted July 5, 2018, Accessed February 13, 2019.
  8. Lilly Press Release, Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial, https://investor.lilly.com/static-files/9117f89a-0f6a-4dd8-a73e-97c108cf613d, Posted November 23, 2016, Accessed February 13, 2019.
  9. Gauthier S, 2016, Alzheimers Dement, 12, P351
  10. Zhang C, 2018, Sci Rep, 8, 1
  11. Aisen PS, 2015, J Prev Alzheimers Dis, 2, 82
  12. Lilly Press Release, Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer’s Disease, https://investor.lilly.com/news-releases/news-release-details/lilly-voluntarily-terminates-phase-ii-study-ly2886721-beta, Posted June 13, 2016, Accessed February 13, 2019.
  13. Pontecorvo MJ, 2017, Brain, 140, 748

Cited by

See all 130

Metadata

Authors
Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E.
Affiliations
  • Massachusetts General Hospital (US)
  • Indiana University School of Medicine (US)
  • University of Southern California (US)
  • Harvard University (US)
  • AZTherapies (United States) (US)
Corresponding author
Elmaleh, David R.
Venue
Journal of Alzheimer’s Disease
Published
2019-08-27
Volume
71
Issue
3
Pages
715-732
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W2971180542
Cited by
129
References
102
Citations by year
2026: 5 · 2025: 12 · 2024: 22 · 2023: 20 · 2022: 16 · 2021: 29 · 2020: 24 · 2019: 1
FWCI
2.06
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (acceptedVersion, cc-by)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
  • PMC
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, disease-modifying drugs
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Humans, Middle Aged, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions. https://app.cochat.ai/papers/10.3233/jad-190507
The paper
Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E. (2019). Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-190507

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.